HVIVO PLC Logo

HVIVO PLC

HVO | IL

Overview

Corporate Details

ISIN(s):
GB00B9275X97
LEI:
213800VT5KBM7JLIV118
Country:
United Kingdom
Address:
QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

hVIVO PLC is a specialist contract research organization (CRO) and a world leader in human challenge clinical trials for testing infectious and respiratory disease vaccines and therapeutics. The company provides end-to-end services, designing and conducting trials where volunteers are safely exposed to a pathogen to accelerate the evaluation of new medical interventions. Its expertise covers a wide range of well-established challenge models for diseases such as Influenza, RSV, COVID-19, hMPV, and Malaria. Leveraging state-of-the-art quarantine facilities, proprietary viral challenge agents, and comprehensive laboratory services, hVIVO supports a global client base of pharmaceutical and biotechnology companies in fast-tracking the development of their products.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for HVIVO PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-29 08:00
Board/Management Information
Proposed appointment of Chair
English 16.3 KB
2025-07-22 08:00
Earnings Release
H1 Trading update
English 26.7 KB
2025-07-18 08:00
Board/Management Information
Directorate Change
English 16.4 KB
2025-07-09 08:00
Report Publication Announcement
Notice of Trading Update
English 17.4 KB
2025-07-01 17:04
Major Shareholding Notification
Holding(s) in Company
English 24.3 KB
2025-06-30 08:00
Earnings Release
Positive results from client Phase 2b field study
English 22.0 KB
2025-06-05 14:00
Post-Annual General Meeting Information
Result of AGM
English 15.3 KB
2025-06-02 08:00
Director's Dealing
Director/PDMR Shareholding
English 48.9 KB
2025-05-30 08:00
Business and Financial Review
Trading update
English 18.7 KB
2025-05-29 08:00
Board/Management Information
Appointment of Independent Non-Executive Director
English 22.6 KB
2025-03-26 14:51
Board/Management Information
AIM Rule 17 and Schedule 2(g) Update
English 15.3 KB
2025-03-07 08:00
Director's Dealing
Director/PDMR Shareholding
English 40.4 KB
2025-02-27 08:00
M&A Activity
Acquisition of Cryostore for up to £3.2m
English 22.4 KB
2025-02-17 08:00
Earnings Release
£2m hMPV characterisation study contract
English 19.3 KB
2025-02-05 08:00
Legal Proceedings Report
Shionogi reports positive RSV trial results
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all HVIVO PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HVIVO PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions for pharma licensing.
France ALNFL
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
Nortem BioGroup Logo
Biotech R&D of natural products for consumer health, home, and animal nutrition.
Spain MLBIO
NRGene Technologies Ltd. Logo
AI genomics software accelerating plant & animal breeding for the agriculture industry.
Israel NRGN
NUFORMIX PLC Logo
A pharma firm repurposing drugs for fibrosis and oncology via proprietary cocrystal technology.
United Kingdom NFX
Nykode Therapeutics ASA Logo
Developing targeted immunotherapies and vaccines for cancer and infectious diseases.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive drugs for sight-threatening eye diseases.
Switzerland OCS
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC